NCT02479178 - A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

January 31, 2020

Conditions

Urothelial CarcinomaCholangiocarcinomaCervical CancerSquamous Cell Carcinoma of Head and Neck

Interventions

DRUG

BIND-014 (docetaxel nanoparticles for injectable suspension)

docetaxel nanoparticles for injectable suspension

Trial Locations (23)

48201

Investigative Site: #34, Detroit

63110

Investigative Site: #34, St Louis

73104

Investigative Site: # 37, Oklahoma City

78229

Investigative Site: # 33, San Antonio

80045

Investigative Site: #39, Denver

85338

Investigative Site: #20, Goodyear

89169

Investigative Site: #43, Las Vegas

94904

Investigative Site: #42, Greenbrae

115478

Investigative Site: #70, Moscow

198255

Investigative Site: #84, Saint Petersburg

Investigative Site: #85, Saint Petersburg

410053

Investigative Site: #88, Saratov

420029

Investigative Site: #75, Kazan'

450054

Investigative Site: #72, Ufa

Unknown

Investigative Site: #74, Arkhangelsk

Investigative Site: #80, Murmansk

Investigative Site: #81, Omsk

Investigative Site: #73, Saint Petersburg

Investigative Site: #78, Saint Petersburg

Investigative Site: #79, Saint Petersburg

Investigative Site: #77, Sochi

Investigative Site: #87, Ulyanovsk

Investigative Site: #82, Yaroslavl